Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Propionsyras inverkan på reglerande T-cellsfunktion hos friska vuxna (Pro-Health) (Pro-Health)

3 november 2026 uppdaterad av: Johannes Benjamin Holle, Charite University, Berlin, Germany

Propionsyras inverkan på reglerande T-cellsfunktion hos friska vuxna.

Pro-Health is a single-center, double-blind, randomized and placebo-controlled intervention study in healthy adults. The investigators address the effect of a dietary food supplementation of propionic acid on the immune system and the function of the intestinal barrier in healhty adults.

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Detaljerad beskrivning

Chronic inflammation is a major risk factor of cardiovascular disease progression in CKD, irrespective of confounding comorbidities. Based on current knowledge, microbially-derived metabolites such as short chain fatty acids (SCFA) play an important role in the regulation of chronic inflammatory processes in CKD patients. Patients with CKD are known to have reduced serum levels of the SCFA propionic acid (PA), as a consequence of both gut microbial dysbiosis and reduced fiber intake. In animal and human studies the impact of PA on function and abundance of regulatory T cells (Treg) has been demonstrated. Consequently, the investigators aim to increase the PA serum levels by oral PA food supplementation in healthy adults in order to perspectively intervene with the same strategy in patients with CKD in the near future, with the target to increase abundance and function of antiinflammatory cells.

Studietyp

Interventionell

Inskrivning (Beräknad)

24

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • State of Berlin
      • Berlin, State of Berlin, Tyskland, 13353
        • Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 40 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • 18 - 40 years old
  • Body weight: > 30kg

Exclusion Criteria:

  • Disease or dysfunctions, which disqualifies the patient
  • Incapacity of contract or any other circumstances, which prohibit the patient from understanding setup, meaning and entity of the study
  • Acute infections
  • Immunosuppressive therapy within the last 12 weeks before the start of the study
  • Pre-/pro- or postbiotic or antibiotic therapy within the last 4 weeks before the start of the study
  • Planned or unplanned hospitalization within in last 4 weeks before the start of the study or during study
  • Malignant diseases
  • Pregnancy
  • chronic gastrointestinal or hepatic diseases (for example chronic inflammatory bowel disease
  • alcohol- or drug abuse
  • parallel participation on other interventional trials

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Grundläggande vetenskap
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Placebo-jämförare: Placebo Intervention

The control-group receives a placebo instead of propionate. The placebo contains maltodextrin and the same amount of sodium chloride as compared to the PA intervention. The placebo is taken twice per day for 28 days.

The patients will be randomized to PA or placebo intervention (2:1 randomization).

After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).

By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.

Experimentell: PA Intervention.

The group which receives the PA as a dietary food supplement. A single capsule contains 500mg of sodiumpropionate, which is taken twice daily for 28 days.

The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.

Andra namn:
  • Propicum

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in count of regulatory T-cells from baseline to week 4
Tidsram: Baseline visit (week 0) in comparison to week 4

Analysis of Treg counts in whole blood (absolute quantification) and peripheral blood

Baseline visit (week 0) in comparison to week 4

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Single cell RNA sequencing of immune cells
Tidsram: Baseline visit (week 0); Week 4

Analysis of the transcriptome of immune cells using cellular indexing of transcriptomes and epitopes (CITEseq)

Baseline visit (week 0); Week 4
Taxonomy of the fecal microbiome
Tidsram: Baseline visit (week 0); Week 4

The taxonomy of the fecal microbiome will be anayzed using 16S RNA amplicon sequencing.

Baseline visit (week 0); Week 4
Propionic acid serum levels and targeted metabolomics
Tidsram: Baseline visit (week 0); Week 2; Week 4

Analysis of PA serum levels and other microbially-derived metabolites by GC-MS and LC-MS

Baseline visit (week 0); Week 2; Week 4
Relative abundance of different immune cell subsets with Immune cell phenotyping of peripheral blood mononuclear cells (PBMC)
Tidsram: Baseline visit (week 0); Week 2; Week 4

Patients PBMC will be thawed and immune cells we be analyzed using multicolor flow cytometry and mass cytometry. By using a broad range of different antibodies combined in several panels the investigators will analyse distinct T cell subtypes including markers of activation, but also other immune cells (including B cells, dendritic cells, monocytes, natural killer cells). Data will reported in relation to parent populations (e.g. T heller cells in % of T cells).

Baseline visit (week 0); Week 2; Week 4
Measuring the suppressive function of regulatory T cells (Tregs) as percentage of proliferated conventional CD4-positive T cells with an in vitro T regulatory cell (Treg) suppression assay
Tidsram: Baseline visit (week 0); Week 4

The suppressive capacity of patients Treg will be analyzed by co-cultivation with conventional, stimulated T cells (Tconv) in different proportions (Treg:Tconv). The proliferation of Tconv will be reported.

Baseline visit (week 0); Week 4
Measuring the intestinal barrier function by measuring the concentration of different leaky gut markers
Tidsram: Baseline visit (week 0); Week 2; Week 4

Analysis of biomarkers for intestinal barrier function, such as sCD14, zonulin-1 and LPS

Baseline visit (week 0); Week 2; Week 4
Cardiovascular Phenothyping
Tidsram: Baseline visit (week 0); Week 2; Week 4

Analysis of heart rate over time.

Baseline visit (week 0); Week 2; Week 4
Cardiovascular Phenotyping
Tidsram: Baseline visit (week 0); Week 2; Week 4

Analysis of blood pressure over time.

Baseline visit (week 0); Week 2; Week 4
Cholesterol levels
Tidsram: Baseline visit (week 0); Week 2; Week 4

Cholestrol levels will be assessed using standard clinical lab values

Baseline visit (week 0); Week 2; Week 4

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

8 januari 2024

Primärt slutförande (Faktisk)

28 februari 2024

Avslutad studie (Beräknad)

30 januari 2027

Studieregistreringsdatum

Först inskickad

27 december 2023

Först inskickad som uppfyllde QC-kriterierna

27 december 2023

Första postat (Faktisk)

10 januari 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • EA2/195/22 (2)

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera